Publicado 08/12/2017 18:39
- Comunicado -

Encouraging Updated Results from Phase 1b/2 Study Evaluating the Combination of Eribulin Mesylate and Pembrolizumab in P

Eribulin is believed to work primarily via a tubulin-based mechanism that causes prolonged and irreversible mitotic blockage, ultimately leading to apoptotic cell death.[8] ,[9] Additionally, in preclinical studies of human breast cancer, eribulin demonstrated complex effects on the tumour biology of surviving cancer cells, including increases in vascular perfusion resulting in reduced tumour hypoxia,[10] and changes in the expression of genes in tumour specimens associated with a change in phenotype, promoting the epithelial phenotype, opposing the mesenchymal phenotype.[10] Eribulin may also decrease the migratory, invasive and metastatic potential of human breast cancer cells.[11],[12], [13],[14]

About Eisai Co Ltd Eisai Co Ltd is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as 'giving first thought to patients and their families and to increasing the benefits health care provides,' which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in multiple therapeutic areas with high unmet medical needs, including Oncology and Neurology. 

For more information about Eisai Co., Ltd., please visit www.eisai.com [https://webmail.hhealth.com/owa/redir.as... ]

References  

1. Tolaney S, et al. (2017) Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium 2017; Program Number: PD6-13.  2. Smith II J, et al. (2017) Phase 2 study evaluating the efficacy and safety of eribulin mesylate administered biweekly for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. San Antonio Breast Cancer Symposium 2017; Poster Session 6: PD-14-05.  3. Kaul R, et al. (2017) Eribulin differentially disrupts TGF-beta signaling pathway in BT-549 and HCC1937 breast cancer cell lines. San Antonio Breast Cancer Symposium 2017; Poster Session 5: P5-04-04.  4. Ferlay J, et al. (2016) More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncologica. 55,1158-1160.  5. O'Shaughnessy J. (2005). Extending survival with chemotherapy in metastatic breast cancer. The Oncologist. 10, 20, 20-29.  6. National Cancer Institute. (2011). SEER Stat fact sheets: Breast cancer. Seer.cancer.gov. Accessed at http://seer.cancer.gov/statfacts/html/br... accessed December 2017].  7. Eisai. Halaven SPC (Updated August 2017). Accessed at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product... /WC500105112.pdf [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... ]  [Last accessed December 2017]. 8. Kuznetsov G, et al. (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockade by halichondrin B macrocyclic ketone analog E7389. Cancer Research. 64,5760-5766. 9. Towle MJ, et al. (2011) Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Research. 71,469-506. 10. Ueda S, et al. (2016) In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab. British Journal of Cancer. 114,1212-1218.  11. Ozawa Y, et al. (2014) Suppression of metastasis and improvement of drug distribution by eribulin mesylate. Poster presented at the 26th EORTC-NCI-AACR symposium 2014; Poster 030. 12. Funahashi Y, et al. (2014) Eribulin mesylate reduces the abnormality of tumor microenvironment by vascular remodelling in human breast cancer models. Cancer Science. 105,1334-1342. 13. Yoshida T, et al. (2014) Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial translation (MET) states. British Journal of Cancer. 110,1497-1505. 14. Agouinik SI, et al. (2014) Eribulin mesylate exerts specific gene expression changes in pericytes and shortens pericyte-driven capillary network in vivo. Vascular Cell. 6,3.

Halaven-EU0477 December 2017

CONTACT: Eisai Europe Ltd: Bily Kuo, +44 (0) 7739 600 678,Bily_Kuo@eisai.net, Helena Symeou, +44 (0) 7507 309 895,Helena_Symeou@eisai.netTonic Life Communications: Rizwan Dasu, +44 (0) 208 747 4440,Rizwan.Dasu@toniclc.com

Comunicados

Si quieres mejorar el posicionamiento online de tu marca, ahora puedes publicar tus notas de prensa o comunicados de empresa en la sección de Comunicados de europa press

Si necesitas asesoramiento en comunicación, redacción de tus notas de prensa o ampliar la difusión de tu comunicado más allá de la página web de europa press, ponte en contacto con nosotros en comunicacion@europapress.es o en el teléfono 913592600